Sector | Trading | Compare with Sector peers |
Industry | Trading | Compare with Industry peers |
Website | http://www.remlife.com | |
Market Cap | 1,093.68 Cr. | |
Enterprise Value(EV) | 1,094.44 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 7.52 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 14.43 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 64.38 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 9.02 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 12.03 | Calculated using Price: 108.50 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 10.08 Cr. | 100,800,000 Shares |
FaceValue | 1 | |
About Remedium Lifecare Ltd. | ||
The company is pharmaceutical company aligned across two business verticals viz. Products and Services. Its Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets. |
1 Day |
|
-1.50% |
1 Week |
|
+8.99% |
1 Month |
|
-11.10% |
3 Month |
|
+6.39% |
6 Month |
|
-25.02% |
1 Year |
|
+376.29% |
2 Year |
|
+2123.36% |
5 Year |
|
+19627.27% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 21.4 | 0.36 | 0.11 | 0.45 | 0.26 | 8.62 | 13.33 | 24.51 | 70.92 | |
Return on Capital Employed (%) | 24.6 | 0.66 | 0.14 | 0.55 | 0.62 | 11.16 | 7.39 | 18.16 | 102.54 | |
Return on Assets (%) | 8.92 | 0.21 | 0.09 | 0.42 | 0.24 | 7.11 | 2.25 | 0.82 | 0.79 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 10 | 22 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 11 | 0 | 9 | ||||
Curr. Liab. | 3 | 2 | 0 | 0 | 0 | 1 | 24 | 219 | 1,144 | 1,875 | |
Minority Int. | |||||||||||
Equity & Liab. | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,906 | |
Non Curr. Assets | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||
Curr. Assets | 3 | 4 | 2 | 2 | 4 | 4 | 38 | 224 | 1,154 | 1,906 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,906 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 2 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 510 | 2,709 | |
Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 18 | |
Total Income | 3 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 511 | 2,727 | |
Total Expenditure | -2 | -4 | -1 | 0 | 0 | -3 | -89 | -503 | -503 | -2,643 | |
PBIDT | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 8 | 84 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Taxation | 0 | 0 | 0 | 0 | 0 | -2 | -8 | ||||
Exceptional Items | |||||||||||
PAT | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 76 | ||
Adjusted EPS | 0 | 0 | 0 | 0 | 1 | 8 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | -1 | 0 | 0 | 0 | 0 | -10 | 11 | 21 | |
Cash Fr. Inv. | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
Cash Fr. Finan. | 0 | 0 | 0 | 0 | 0 | 10 | -11 | 0 | |||
Net Change | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 20 | ||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 22 |
Wed, 27 Mar 2024
Announcement under Regulation 30 (LODR)-Change in Management In terms of Regulation 30 of SEBI (LODR) Regulations 2015 1. Appointment of Ms. Seema Sanei (DIN: 10549952) as an Additional Independent Director of the Company to hold an office for term of three years subject to approval of Shareholders.2. Appointment of Mr. Pratik Shah (DIN: 6809235) as an Additional Independent Director of the Company to hold an office for term of three years subject to approval of Shareholders. |
Tue, 26 Mar 2024
Closure of Trading Window Intimation of closure of Trading Window pursuant to the provisions of SEBI (Prohibition of Insider Trading)Regulation 2015 |
Thu, 07 Mar 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.03.2024 Regarding Intimation Under SEBI(Listing Obligation And Disclosure Requirements) Regulations 2015 This is to inform you that the Board of Directors of the Company at its meeting has proposed to acquire a Manufacturing Facility in Hyderabad situated at Phase 2 Survey No.10 Gaddapotharam Industrial Area Jinnaram Mandal Medak Sangareddy District Hyderabad-502319 Telangana India. having an area of 130680 square feet. The unit is well equipped to produce Intermediates for the Pharmaceutical Industry. |
Thu, 28 Mar 2024 |
Close Above Last Week High |
High Decrease in 1 Month |
High Decrease in 6 Months |
High Increase in 1 Year |
High Increase in 2 Years |